Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 103M | 31.1% |
| Gross Profit | 96M | 31.9% |
| Cost of Revenue | 6.2M | 19.7% |
| Operating expense | 119M | 19.3% |
| Net Income | -20M | 19% |
| EBITDA | -18M | 32.9% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 495M | 1.1% |
| Total Liabilities | 162M | 2.6% |
| Total Equity | 333M | 2.9% |
| Shares Outstanding | 42M | 7.7% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -29M | 42.3% |
| Cash from investing | -52M | 48% |
| Cash from financing | 2M | 98.6% |
EPS
Financial Highlights for Tarsus Pharmaceuticals in Q2 '25
Tarsus Pharmaceuticals reported a revenue of 103M, which is a 31.1% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 96M, marking a 31.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 6.2M, a 19.7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 119M, showing a 19.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -20M, showing a 19% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -18M, showing a 32.9% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Tarsus Pharmaceuticals with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
